Novo raises 2026 guidance as Wegovy pill sales beat forecasts
The oral semaglutide product logged about 1.3 million US prescriptions in its first full quarter on the market, roughly double analyst sales estimates.
The wire
- 01Novo Nordisk reported Wegovy pill sales of 2.26 billion kroner against analyst estimates of 1.16 billion, and raised full-year adjusted guidance to a 4% to 12% contraction.
- 02Oral semaglutide uptake alongside injectables matters for pharmacies and telehealth operators planning inventory; CEO Mike Doustdar said Wegovy holds 65% of new US prescriptions.
- 03Novo plans to launch the Wegovy pill outside the US in the second half of 2026 pending approvals, while Ozempic sales fell 8% and Lilly's oral rival Foundayo launched in April.
From the source
Read at cnbc.comWegovy pill sales smash forecasts, sending Novo Nordisk stock higher
Novo Nordisk hiked its annual profit guidance on Wednesday, as the drugmaker said its Wegovy weight-loss pill performed better than expected in the first three months of the year, sending its shares higher.